Solving ADMET Challenges in Antibiotic Development: Real-World DMPK Strategies
Antibiotic development often falters due to unresolved ADMET challenges, rather than a lack of efficacy. This talk will highlight how DMPK tools such as prodrug design, liposomal delivery, metabolic profiling, and PBPK modelling can address these limitations. Through practical case studies, Dr. Kotakonda will outline strategies to optimize safety, efficacy, and regulatory outcomes, offering a robust framework for integrating DMPK into antibiotic development.
Role of DMPK in Prodrug Development
Prodrugs can improve pharmacokinetic profiles and reduce toxicity, but they also present unique analytical challenges. Mr. Rambabu Pattem’s talk will explore DMPK-guided approaches to identify structural soft spots, avoid reactive metabolite formation, and overcome LCMS/MS hurdles. Case studies and screening strategies will demonstrate how to design prodrugs with favorable ADME properties, supporting both safety and efficacy from discovery through development.
The development of novel antibiotics and prodrugs presents exciting opportunities but is often hampered by complex ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) challenges. From poor solubility and limited permeability to the formation of reactive metabolites, these issues can derail drug development if not addressed early. In this scientific webinar, our expert panel explores how DMPK strategies can help overcome these roadblocks through translational insights and real-world frameworks.
Speaker Bio
Harish Kaushik Kotakonda, Ph.D.
Dr. Harish Kotakonda is a clinical pharmacologist with over 18 years of experience in DMPK and regulatory strategy across multiple therapeutic areas. He has contributed to 10 IND-stage and 5 approved NDA programs and has expertise in PBPK modelling, pharmacometrics, and clinical operations. He is the co-inventor of five patents filed in international and national jurisdictions.
Vishwottam Kandikere Ph.D.
Dr. Vishwottam Kandikere is a global clinical pharmacokineticist with 25 years of experience. He has contributed to 13 NCEs, holds 11 US patents, and has authored over 90 publications. His work spans therapeutic areas such as neuroscience, oncology, and metabolic disorders. He has successfully led the discovery and optimization of 13 NCEs from bench to early clinical trials. Dr. Kandikere holds a Ph.D. in Pharmaceutical Analysis from Jawaharlal Nehru Technological University, Hyderabad.
Rambabu Pattem
Mr. Rambabu Pattem brings over 23 years of experience in DMPK, with deep expertise in biotransformation, LCMS-based bioanalysis, and early-phase clinical studies. He has worked extensively on small molecules, peptides, and biologics across multiple CROs and discovery platforms. He has published five research articles in peer-reviewed journals. Rambabu completed his M. Pharmacy from Andhra University, Visakhapatnam.
